Overview

A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112

Status:
Completed

Trial end date:
2021-11-20

Target enrollment:

Participant gender:

Summary

To evaluate safety, tolerability and pharmacokinetics of NCP 112 after single and multiple applications on the skin of healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

NovaCell Technology Inc.